16 Oct 2026

CRC Research Update — October 16, 2026

Creator: The CRC Digest
Published: 2026-10-16T11:31:05Z

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
Early-Onset CRC Shows Distinct Mutation Profile in Meta-Analysis of 154,982 Patients
A systematic review found that colorectal cancer diagnosed before age 50 has higher frequencies of TP53 and SMAD4 mutations and lower frequencies of APC, KRAS, and BRAF mutations compared to late-onset disease, suggesting different mechanisms of cancer development in younger adults. (Cancers)
TREATMENT
Liquid Biopsy Retesting May Predict Benefit from Anti-EGFR Rechallenge
(Neoplasma)
RESEARCH
RAS Mutation Status Remains Prognostic After Metastasectomy
Among 290 Brazilian patients with stage IV colorectal cancer, RAS wild-type status was independently associated with improved survival even in the subset who underwent metastasectomy, suggesting tumor biology continues to influence outcomes after surgical resection. (Cancers)
SCREENING
Czech National Screening Program Reports 50% Mortality Decline Over 25 Years
Age-standardized colorectal cancer mortality in the Czech Republic fell 50% between 1998–2000 and 2022–2024, coinciding with a national screening program that detected cancer in 16,575 of 653,825 preventive colonoscopies. (Cancers)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Younger Patients Show Higher TP53 and SMAD4 Mutations
Meta-analysis of 43 studies found early-onset CRC has higher TP53 and SMAD4 mutation frequencies and lower APC and KRAS mutations, highlighting distinct molecular pathways in younger adults. (Cancers)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Non-Aspirin NSAIDs Associated with Lower Adenoma Detection
Among 64,889 Norwegian screening participants, use of non-aspirin NSAIDs was associated with lower odds of adenomas and advanced adenomas, with stronger effects seen in long-term users. (Gastroenterology Reports)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

Treatment Sequencing After Immunotherapy Progression in MSI-H/dMMR Disease
A clinical review proposes an evidence-informed framework for managing progression after immune checkpoint blockade in MSI-H/dMMR metastatic CRC, noting that BRAF V600E is common but not an absolute predictor of immunotherapy failure. (Journal of Gastrointestinal Cancer)

This week's research continues to refine molecular profiling and treatment sequencing across disease stages and age groups.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest